This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Chemokine (C-X-C motif) ligand 14 (CXCL14; BRAK)	<p><i>In vitro</i> and mouse studies suggest that antagonizing CXCL14 could help treat prostate cancer. In human prostate cancer-associated fibroblasts, CXCL14 was upregulated compared with that seen in noncancerous tissue. In a mouse xenograft prostate cancer model, injection of CXCL14-expressing fibroblasts increased angiogenesis and macrophage density, resulting in larger tumors compared with what was seen in controls that did not express CXCL14. Next steps include developing CXCL14 antagonists. At least seven companies have compounds targeting CXC chemokine receptors in development stages ranging from preclinical to approved to treat cancer.</p> <p>SciBX 2(7); doi:10.1038/scibx.2009.273 Published online Feb. 19, 2009</p>	Findings unpatented; unavailable for licensing	<p>Augsten, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 9, 2009; doi:10.1073/pnas.0813144106 Contact: Arne Östman, Karolinska Institute, Stockholm, Sweden e-mail: arne.ostman@ki.se</p>